Insulin Sensitivity Is Reflected by Characteristic Metabolic Fingerprints - A Fourier Transform Mass Spectrometric Non-Targeted Metabolomics Approach by Lucio, Marianna et al.
Insulin Sensitivity Is Reflected by Characteristic
Metabolic Fingerprints - A Fourier Transform Mass
Spectrometric Non-Targeted Metabolomics Approach
Marianna Lucio
1, Agnes Fekete
1, Cora Weigert
2,3, Brigitte Wa ¨gele
4,5, Xinjie Zhao
6, Jing Chen
6, Andreas
Fritsche
3,7, Hans-Ulrich Ha ¨ring
3,7, Erwin D. Schleicher
2,3, Guowang Xu
5, Philippe Schmitt-Kopplin
1,8*,
Rainer Lehmann
2,3*
1Department of BioGeoChemistry and Analytics, Institute for Ecological Chemistry, Helmholtz-Zentrum Muenchen - German Research Center for Environmental Health,
Neuherberg, Germany, 2Central Laboratory, Division of Clinical Chemistry and Pathobiochemistry, University Hospital Tuebingen, Tuebingen, Germany, 3Paul-
Langerhans-Institute Tu ¨bingen, Member of the German Centre for Diabetes Research (DZD), Eberhard Karls University Tu ¨bingen, Tu ¨bingen, Germany, 4Institute of
Bioinformatics and Systems Biology, Helmholtz-Zentrum Muenchen - German Research Center for Environmental Health, Neuherberg, Germany, 5Department of Genome
Oriented Bioinformatics, Life and Food Science Center Weihenstephan, Technische Universita ¨tM u ¨nchen, Freising-Weihenstephan, Germany, 6CAS Key Laboratory of
Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China, 7Department of Internal Medicine 4,
University Hospital Tuebingen, Tuebingen, Germany, 8Department for Chemical-Technical Analysis Research Center Weihenstephan for Brewing and Food Quality,
Technische Universita ¨tM u ¨nchen, Freising-Weihenstephan, Germany
Abstract
Background: A decline in body insulin sensitivity in apparently healthy individuals indicates a high risk to develop type 2
diabetes. Investigating the metabolic fingerprints of individuals with different whole body insulin sensitivity according to
the formula of Matsuda, et al. (ISIMatsuda) by a non-targeted metabolomics approach we aimed a) to figure out an
unsuspicious and altered metabolic pattern, b) to estimate a threshold related to these changes based on the ISI, and c) to
identify the metabolic pathways responsible for the discrimination of the two patterns.
Methodology and Principal Findings: By applying infusion ion cyclotron resonance Fourier transform mass spectrometry,
we analyzed plasma of 46 non-diabetic subjects exhibiting high to low insulin sensitivities. The orthogonal partial least
square model revealed a cluster of 28 individuals with alterations in their metabolic fingerprints associated with a decline in
insulin sensitivity. This group could be separated from 18 subjects with an unsuspicious metabolite pattern. The orthogonal
signal correction score scatter plot suggests a threshold of an ISIMatsuda of 15 for the discrimination of these two groups. Of
note, a potential subgroup represented by eight individuals (ISIMatsuda value between 8.5 and 15) was identified in different
models. This subgroup may indicate a metabolic transition state, since it is already located within the cluster of individuals
with declined insulin sensitivity but the metabolic fingerprints still show some similarities with unaffected individuals (ISI
.15). Moreover, the highest number of metabolite intensity differences between unsuspicious and altered metabolic
fingerprints was detected in lipid metabolic pathways (arachidonic acid metabolism, metabolism of essential fatty acids and
biosynthesis of unsaturated fatty acids), steroid hormone biosyntheses and bile acid metabolism, based on data evaluation
using the metabolic annotation interface MassTRIX.
Conclusions: Our results suggest that altered metabolite patterns that reflect changes in insulin sensitivity respectively the
ISIMatsuda are dominated by lipid-related pathways. Furthermore, a metabolic transition state reflected by heterogeneous
metabolite fingerprints may precede severe alterations of metabolism. Our findings offer future prospects for novel insights
in the pathogenesis of the pre-diabetic phase.
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In the pathogenesis of type 2 diabetes mellitus initial metabolic
alterations occur even decades before the manifestation of this
epidemic lifestyle disease [1,2]. This long asymptomatic period
represents the so called pre-diabetic state. It is dominated by a
gradually developing insulin resistance of skeletal muscle, liver and
fat tissue as well as the dysregulation of insulin secretion. However,
in contrast to the evident diabetic state the mechanisms related to
the decline in insulin sensitivity, in particular the altered metabolic
pathways and the transition process, are much less clear.
Metabolomics tools have been proven in several recent human
studies to fulfill the prerequisite to study metabolic alterations of
body fluids for the discrimination between states of health and
disease [3–10]. Manifest type 2 diabetes has been investigated in
several recent targeted- and non-targeted- (NT-) human studies
[11–20]. Metabolomics approaches have also been taken to study
the effects of anti-diabetic drugs on the metabolite pattern and the
affected pathways in type 2 diabetic subjects [21,22]. However,
metabolite patterns from pre-diabetic humans have mostly been
studied by targeted profiling strategies only [14,19,23–25]. NT-
metabolomics investigations of plasma from pre-diabetic subjects
by ion cyclotron resonance Fourier transform mass spectrometry
(ICR-FT/MS) has not been carried out so far. In total, only a few
applications of ICR-FT/MS analyzing metabolites in plasma
samples in the flow injection mode can be found [26,27]. Using
ICR-FT/MS with high magnetic fields (12 Tesla) enables the
highest resolution (400.000 at m/z 400) combined with the best
mass accuracy (,200 ppb) for a direct conversion of the
experimental mass into elementary compositions. Previous meta-
bolomics studies showed that this technology together with
multivariate statistics and bioinformatics allows to differentiate
thousands of exact mass signals [28]. These could be directly
annotated to probable metabolites and their isomers with
information on metabolic pathways [28,29] from existing
databases [30].
In our NT-metabolomics ICR-FT/MS study we first aimed to
group 46 non-diabetic subjects into metabolic healthy individuals
and indviduals with reduced insulin sensitivity. To this end,
individual metabolic fingerprints detected in the plasma by ICR-
FT/MS were correlated with the insulin sensitivity index
calculated according to Matsuda [31]. A second objective of our
study was to identify the metabolic pathways that are most affected
by the decline in insulin sensitivity. This goal was achieved by
translating the detected metabolite ions into pathways using the
metabolic annotation interface MassTRIX which assigns to each
m/z value potential annotations from various metabolite data
bases [30]. NT-metabolomics analysis by ICR-FT/MS combined
with bioinformatics approaches revealed three clusters of different
metabolic fingerprints, namely, an insulin sensitive group,
individuals in a metabolic transition state, and subjects with a
metabolic fingerprint associated with a clear decline in insulin
sensitivity. Furthermore, alterations of distinct metabolic pathways
were detected which offer novel insights into the switch of
individual metabolite pattern along with the decline in insulin
sensitivity.
Results and Discussion
Investigation of the metabolic conversion from normal to
reduced insulin sensitivity reflected by individual
metabolite fingerprints
In non-diabetic individuals a decline in whole body insulin
sensitivity indicates a high risk to develop type 2 diabetes. One of
the most widespread indices used in clinical and research settings
to estimate whole body insulin sensitivity is the insulin sensitivity
index proposed by Matsuda and DeFronzo [31] (ISIMatsuda) which
is derived from oral glucose tolerance test (oGTT) data. It reflects
a composite estimate of hepatic and muscle insulin sensitivity,
which decline in the pre-diabetic metabolic state resulting in a
lower ISIMatsuda value [31,32]. Of note, to the best of our
knowledge only a threshold to identify diabetic subjects (ISIMatsuda
,2.5) can be found in the literature [32,33], but no ISIMatsuda
threshold for the identification of insulin resistant pre-diabetic
subjects has been determined so far. Aiming in a first step to
differentiate subjects with decreased insulin sensitivity (= low
ISIMatsuda) from those with normal ISIMatsuda levels based on the
individual metabolite patterns we applied a NT-metabolomics
ICR-FT/MS-driven analysis of plasma samples leading to mass
spectra containing up to 2958 metabolite ion masses per
individual. We hypothesized that a relationship could exist
between the set of variables (m/z values of ion masses) and the
ISIMatsuda values. In order to validate this hypothesis we built up a
partial least square (PLS) model where the dependent variable Y
was set to ‘‘Insulin Sensitivity Indices’’. A three components model
was found optimal using a cross validation approach provided by
SIMCA-P 12 [34]. Subsequently, this model was internally
validated using the permutation testing routine [35]. 200
randomly permuted models showed all less significance than the
original model. Additionally, no sign of overfitting was detected.
The orthogonal signal correction-partial least-squares (OSC-
PLS) score scatter plot (Figure 1A) suggests that the metabolite
pattern of individuals with an ISIMatsuda around 15 already differs
from the one of individuals with lower ISI values. This gives a
first hint that an ISIMatsuda threshold for the pre-diabetic state
would be considerably higher than the threshold of ,2.5, which
has been established for the detection of diabetic subjects [32,33].
Next, we performed further multivariate investigations of the
characteristics of the metabolic fingerprints applying an orthog-
onal-partial least-squares (OPLS/O2PLS) model. We detected a
subgroup of eight subjects which fit in part to the metabolite
pattern of the group with low insulin sensitivity, but also match to
some extent to the group with normal insulin sensitivity.
Therefore, we hypothesize that the metabolite pattern of these
individuals (ISIMatsuda value ranges between 8.5 and 15) may
represent some kind of metabolic transition state from normal to
reduced ISI values.
In the next step we analyzed the data for more pronounced
similarities between the transition group on one hand and either
the group with normal or impaired insulin sensitivity on the other.
Figure 1B shows the projection of the transition samples in the
next OPLS-DA model generated. The score scatter plot of the first
component tPS[1] shows the prediction of the transition group,
used as external dataset. From this visualization it could be
concluded that the transition group shows properties closer to the
class of subjects with reduced ISI values (ISIMatsuda ,8.5).
Assuming that the transition group belongs to the class with
reduced insulin sensitivity, an OPLS model was generated where
only two classes were defined (ISIMatsuda ,15 and ISIMatsuda .15).
Figure 1C shows two distinct clusters with an ISIMatsuda of 15 as
threshold. Of note, the Cross Validation-ANOVA (CV-ANOVA)
of the model had a high significance (p=4.76199610
219) and the
validity of the model was also confirmed by the values R
2(Y)=0.96
and Q
2(cum)=0.93. These findings confirm the hypothesis that
the metabolic patterns of the transition group are more similar to
the group with decreased ISI. As a further confirmation of the ISI
threshold of 15, clustering into two groups was not possible for
models generated with values lower than 15, (data not shown).
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from normal to reduced insulin sensitivity
To screen for the pathways most affected in individuals with
decreased insulin sensitivity the NT-metabolomics data were
evaluated using MassTRIX [30]. The metabolite ion masses with
the highest regression coefficients were considered as discriminants
for the two classes. From the total of detected masses, 4847 m/z-
values were selected as being typical for individuals with an ISI
value ,15, and 5035 for those with an ISI .15.
To annotate putative metabolites and the corresponding
pathways these selected masses were uploaded into MassTRIX
[30]. Only 19% of the mass signals could be assigned to
metabolites; all others, including isotopologues are important
unknown chemical structures (data not shown). The pathways
potentially affected by differential metabolite intensities in the two
groups are given in Table 1. This analysis revealed that
arachidonic acid metabolism, steroid hormone biosyntheses, bile
acid metabolism, metabolism of essential fatty acids (linoleic and
a-linolenic acid) and biosynthesis of unsaturated fatty acids
comprise the highest number of intensity differences in known
detected metabolites between the two groups (Table 1). Of note,
not all of these compounds are unique for the respective pathway.
For example, we found 40.2% of unique compounds in
arachidonic acid metabolism, 61.9% in steroid hormone biosyn-
thesis, 40.9% in bile acid biosynthesis, 69.2% and 45%,
respectively for a-linolenic acid metabolism and linoleic acid
metabolism, and 38.9% in the pathway of the biosynthesis of
unsaturated fatty acids.
Alterations in the metabolism of essential fatty acids and
polyunsaturated fatty acids are discussed to play a significant role
in the pathophysiology of metabolic syndrome and diabetes
mellitus [36]. A targeted metabolomic investigation of the plasma
pattern of families burdened with early-onset cardiovascular
disease revealed linoleic acid (LA) and arachidonic acid (AA) as
biomarkers [37]. Bile acids, having for a long time been viewed
solely as detergents that emulsify nutrient lipids, are now discussed
as metabolic integrators of whole-body energy homeostasis that
influence glucose and lipid metabolism [38]. In addition, bile acids
were among the metabolites showing the most striking changes
during an oGTT in a targeted metabolic profiling approach [14]
and in a non-targeted metabolomics study recently performed by
our group [17].
Since the annotated pathways of arachidonic, linoleic and a-
linolenic acid as well as the biosynthesis of unsaturated fatty acids
are interrelated and comprise a high number of metabolites with
altered intensities (Table 1) we focussed in more detail on the
metabolite ion masses of those pathways.
Investigation of dominating pathways reflecting
conversion from normal to reduced insulin sensitivity
In a first step a metabolite heat map was generated solely based
on the metabolite ion masses of the pathways of a-linolenic acid,
linoleic acid, arachidonic acid, and biosynthesis of unsaturated
fatty acids (Fig. 2). The heat map was divided into three sections
representing individuals with declined ISIMatsuda, metabolic
transition state and normal ISIMatsuda, respectively.
In normal controls green shades dominate (Fig. 2), representing
low relative metabolite concentrations. In subjects with declined
insulin sensitivity and in the transition group dark shaded colours
predominate, representing medium to high relative metabolite
concentrations. However, the heat map also reveals a high
interindividual variability (Fig. 2). Particularly in the group with
declined insulin sensitivity the patterns of the individuals with an
ISI of 7.58, 7.71 and 8.06 were highly different from the patterns
of the other individuals within this group.
Since the heat map patterns of individuals with declined
ISIMatsuda, metabolic transition state and normal ISIMatsuda clearly
showed distinct trends but also high interindividual variability we
speculated about the discrimination power of these four pathways.
Therefore, we further investigated the impact of these four
pathways by generating a score scatter plot based solely on the
metabolite signal intensities of a-linolenic acid and linoleic acid,
arachidonic acid pathway, and biosynthesis of unsaturated fatty
acids. Fig. 3 demonstrates a separation of the groups of individuals
with an ISIMatsuda ,8.5 and .15, the only exception being two
individuals with an ISIMatsuda of 7.58 and 8.36 who show closer
similarity to the group with normal insulin sensitivity. The
transition group (labelled by triangles) in the score scatter plot
Table 1. Metabolic pathways altered in subjects with
reduced insulin sensitivity (ISIMatsuda ,15) in descending order
of the number of detected differing metabolites.
Pathway description
Count diff.
metabolites
Arachidonic acid metabolism (hsa00590)
a 77
Steroid hormone biosynthesis (hsa00140)
a 71
Bile acid biosynthesis (hsa01120)
a 22
Linoleic and a-Linolenic acid metabolism (hsa00591,
hsa00592)
a
33
Biosynthesis of unsaturated fatty acids (hsa01040)
a 18
Porphyrin metabolism (hsa00860)
a 16
Retinol metabolism (hsa00830)
a 15
Sphingolipid metabolism (hsa00600)
a 14
Galactose metabolism (hsa00052)
a 12
Fructose and mannose metabolism(hsa00051)
a 11
Phenylalanine metabolism (hsa00360)
a 10
Fatty acid biosynthesis (hsa00061)
a 10
a)KEGG pathway number.
Pathways with less than 10 metabolites differing between individuals with
reduced and normal insulin sensitivity are not shown. By comparing the exact
experimental mass signals (threshold set as signal to noise $3) with the
theoretical masses in MassTRIX, the counts of metabolites were obtained and
could be assigned to the different metabolic pathways.
doi:10.1371/journal.pone.0013317.t001
Figure 1. Investigation of individual metabolite fingerprints reflecting the metabolic conversion from normal to reduced insulin
sensitivity. (A) Individual ISIMatsuda values (to the right of each dot) assigned to the metabolite fingerprints in an OSC-PLS score scatter plot t[1]u[1]
achieving R
2(Y)=0.94 and Q
2(cum)=0.90. (B) Score scatter plot of the first component tPS[1] against ISIMatsuda values using the transition group as
external dataset. From this visualization it was inferred that the transition group revealed properties closer to the class of subjects with reduced ISI
values. (C) A threshold of ISIMatsuda =15 was set to generate an OPLS model showing a clustering into two groups of subjects, i.e. with normal and
declined insulin sensitivity. Using CrossValidation-ANOVA the model showed a high significance (p=4,76199610
219). Furthermore, the model
achieved the following parameters: R
2(Y)=0.96 and Q
2(cum)=0.93. Definition of labels: (m) ISIMatsuda level , 8.5, (*) ISIMatsuda from .8.5 and ,15, and
(N) ISIMatsuda .15.
doi:10.1371/journal.pone.0013317.g001
Metabolome of Pre-Diabetics
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13317(Fig. 3) was again identified as an intermediate state. These data
reveal a potential relevance of alterations of these four pathways in
the mechanistic scenario of reduced insulin sensitivity.
It is important to note that differences between means of most
metabolite signals of the four pathways investigated in the heat
map (Fig. 2) and the score scatter plot (Fig. 3) did not reach
statistical significance applying non parametric Wilcoxon rank
sum test because of great interindividual variabilities of the
metabolite signal intensities. However, evaluating the total list of
metabolite ion masses we detected significant differences exem-
plarily shown in Figure 4 for the metabolite ions with the
elementary composition of C37H66O5 (m/z=613.48004 for
Figure 2. Heat map of plasma metabolites from linoleic acid (LA), a-linolenic acid (ALA), arachidonic acid (AA) pathways and
biosynthesis of unsaturated fatty acid (BUFA). The heat map represents the signal intensities of 18 subjects with normal insulin sensitivity
(ISIMatsuda .15), eight individuals who are in the metabolic transition state and 20 individuals with declined insulin sensitivity (ISIMatsuda ,15).
Individual ISIMatsuda levels in increasing order are given in the column at the bottom. Cells are coloured based on the signal intensity measured in
plasma. Shades of red to green represent high to low signal intensities of the metabolite ions in plasma (see color scale on the right side of the heat
map). A yellow line is drawn at an ISIMatsuda value of 15 to mark the potential ISIMatsuda threshold separating individuals with altered and normal
insulin sensitivity revealed in our NT-metabolomics approach. A dash dotted white line drawn at an ISIMatsuda value of 8.5 marks the suggested
threshold between individuals with distinct insulin resistant metabolic alterations and subjects who are in the metabolic transition state.
doi:10.1371/journal.pone.0013317.g002
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+; possible assignment: Diacylglycerol), and
C41H83N2O6P (m/z=731.60628, [C41H84N2O6P]
+ possible as-
signment: Sphingomyelin).
The metabolite ion possibly assigned to diacylglycerol (DAG)
showed significantly increased levels in individuals with reduced
insulin sensitivity (ISIMatsuda below 8.5) as well as in the
transition group (Fig. 4A). DAG has long been discussed as a
key lipid intermediate linking nutrient excess to dysregulation
of insulin action [39]. A large dietary fat load may lead to
accumulation of diacylglycerols and subsequently to activation of
protein kinase C isoforms [40]. Furthermore, the intramyocel-
lular concentration of DAG in skeletal muscle has been shown to
increase in insulin-resistant rodents and humans [40]. Since
DAG concentrations appeared to be similarly elevated in both
the transition group and the insulin resistant group (data not
shown), this increase could represent an early event in the
development of insulin resistance.
Another example of a metabolite found to be increased in the
pre-diabetic group (ISIMatsuda ,15) compared to the group with
normal insulin sensitivity is the metabolite ion possibly assigned to
sphingomyelin (Fig. 4B). Sphingomyelin is also among the
candidate molecules likely involved in pathomechanisms relevant
for a decline in insulin sensitivity, since the breakdown of
sphingomyelin leads to the generation of ceramide which is a
potent signaling molecule well known to mediate insulin resistance
[39–41]. It appears worthwhile to verify the identity of this
metabolite and to investigate its plasma concentration in larger
cohorts in order to determine whether it is a transient marker for a
very early state of declining insulin sensitivity.
A further interesting observation was the detection of a
metabolite with the elemental composition C33H42N4O6 (possible
assignment: Urobilinogen) in seven individuals with an ISI ,8.5
(data not shown). This finding is of potential interest since this
metabolite was neither detectable in individuals of the transi-
tion group nor in the group with normal insulin sensitivity.
Urobilinogen is a product of bilirubin metabolism, formed by
intestinal reduction through bacteria of the gut flora. It is mainly
excreted in faeces, but a small amount is reabsorbed in the
terminal ileum and colon and enters the enterohepatic circulation
(called the ‘‘enterohepatic urobilinogen cycle’’) from where a
minor fraction is excreted by the kidney. Hence, the hepatic
metabolisms as well as the gut flora and to a lesser extent the
kidney are involved in its metabolism and may affect the
urobilinogen plasma levels in subjects with reduced insulin
sensitivity.
In conclusion, out of thousands of m/z signals obtained with the
ICR-FT/MS approach we detected characteristic metabolite
fingerprints in plasma of 46 individuals displaying different insulin
sensitivities. These findings allowed us to divide the subjects into
two groups, one with unsuspicious metabolic pattern and the other
with reduced insulin sensitivity. Furthermore, the results suggest
an ISIMatsuda .15 as a potential threshold to discriminate between
these two groups. The decline in insulin sensitivity was reflected by
alterations in various metabolic pathways. However, many
metabolite ion masses that are not covered by current databases
still have to be elucidated to give a proper view of the whole
metabolic network affected in subjects at high risk to develop
future type 2 diabetes.
Figure 3. Discrimination power of the signal intensities of four selected pathways. A score scatter plot of metabolite ion masses solely
related to the pathways of linoleic acid, a-linolenic acid, arachidonic acid pathways and biosynthesis of unsaturated fatty acid was generated. The
classes in the score scatter plot are defined as: (N) ISIMatsuda .15; (m) ISIMatsuda ,8.5 and (*) transition group (ISIMatsuda .8.5 and ,15).
doi:10.1371/journal.pone.0013317.g003
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Ethics Statement, subjects and study design
The protocol (422/2002) was approved by the Institutional
Review Board of the University of Tuebingen, Schleichstr. 8,
72076 Tuebingen (board chairman: Prof. Dr. D. Luft) according
to the Declaration of Helsinki, and all subjects gave written
informed consent before the study commenced. The investigation
was conducted in accordance with the ethical principles of Good
Clinical Practice. For our study group fifty individuals having
fasting blood glucose levels between 4.5 and 6.5 mmol/l (mean:
5.360.53 mmol/l) which are all below the current diagnostic
criteria of the WHO for type 2 diabetes [42], were recruited.
Hemoglobin A1c (HbA1c) levels were between 4.4 and 6.5%
(mean: 5.560.44%). Eight individuals were in the HbA1c range of
6.0 to 6.5%, recently discussed by the ‘‘International Expert
Committee Report’’ to reflect individuals at highest risk for
progression to diabetes [43]. In our study group glucose, HbA1c,
age (mean: 48.3610.3 years) and waist-to-hip-ratio (0.8760.088)
were normally distributed. After an overnight fast all individuals
underwent a 75 g oral glucose tolerance test (oGTT) under
standardized conditions in the metabolic ward at the University
Clinic in Tuebingen (Germany) according to the recommenda-
tions of the WHO [42]. Venous blood samples were obtained at 0,
30, 60, 90 and 120 minutes of the oGTT for determination of
plasma glucose and insulin. Based on the definition of the WHO
concerning the 120 min blood glucose concentration during an
oGTT [42] four subjects were diagnosed to have type 2 diabetes
and were excluded from the study. From the remaining 46 subjects
insulin sensitivity indices (ISI) were calculated applying the
formula proposed by Matsuda and DeFronzo [31], henceforth
referred to as ISIMatsuda. The ISIMatsuda ranged from 2.48 to 41.47
in our study population. Glucose was measured with the ADVIA
1650 clinical chemical analyzer and insulin with the ADVIA
Figure 4. Comparison of the signal intensities of diacylglycerol and sphingomyelin in plasma of individuals with reduced and
normal insulin sensitivity. A non parametric Wilcoxon rank sum test was applied on the signal intensities of the ions with the elemental
composition of (A)C 37H66O5 (possible assignment: Diacylglycerol) and (B)C 41H83N2O6P (possible assignment: Sphingomyelin) to evaluate statistical
significances between the two groups (ISI ,15 (n= 28) vs. ISIMatsuda .15 (n= 18)). On the right side the corresponding individual ICR-FT/MS spectra
of the nominal masses are given; green = ISI .15 and red = ISI , 15. Mean peak areas 6 standard error are shown, statistical significance (*) was set
at p,0.05.
doi:10.1371/journal.pone.0013317.g004
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Siemens Healthcare Systems (Fernwald, Germany). HbA1c was
determined by cation-exchange HPLC (Tosoh, Germany).
Sample preparation for the NT-metabolomic analysis
The plasma samples (n=46) collected in the fasting state were
aliquoted in volumes of 200 ml and immediately stored at 280uC.
Aliquots were thawed on ice, 50 ml were diluted with 50 ml water
to a final volume of 100 ml. The samples were acidified by the
addition of 10 ml 25% formic acid prior to solid phase extraction
(SPE). SPE was done using OMIX Tip C18 (Varian). The
cartridges were conditioned by flushing the tips ten times with
100 ml methanol followed by 100 ml of water acidified with formic
acid (100 ml water and 5 ml 25% formic acid). Next, the OMIX tip
was flushed ten times with the acidified sample and subsequently
washed one time with 100 ml water acidified with formic acid. The
compounds were then eluted by flushing the tips ten times in
100 ml methanol and were ready for infusion analysis.
Mass spectrometric procedure
High-resolution mass spectra were acquired on a Bruker
(Bremen, Germany) APEX Qe Fourier transform ion cyclotron
resonance MS equipped with a 12 Tesla superconducting magnet
and an Apollo II source. The samples were infused and ionized by
TriVersa Nanomate chip electrospray system (Advion, Ithaca,
USA) in positive mode. After optimisation the chip voltage was set
to 1.6 kV, and a backpressure of 0.5 psi was used. The MS
sampling electrodes, consisting of the spray shield and the metal
cap mounted on the high-pressure side of the transfer capillary,
were both set to 0 V. A drying-gas flow of 4 L6min
21 at 200uC
was used. The spectra were acquired with a time domain of 1 MW
over a mass range of 100–2000 m/z. Two hundred fifty six scans
were accumulated for each spectrum. Spectra were externally
calibrated first on clusters of arginine (10 mg/l in methanol) and
internally calibrated on solvents impurities (diester); calibration
errors in the relevant mass range were always below 100 ppb.
Data acquisition and handling were performed by using the Data
Analysis Software v.3.4 (Bruker Daltonics, Bremen, Germany).
Peaks exceeding a threshold signal-to noise ratio of 3 were
exported to peak lists.
Data analysis
The spectra exported from DataAnalysis were aligned through
in-house software; the data were stored in a matrix by aligning all
the peaks within an error of 1 ppm. The total numbers of
individual variables (m/z) for all samples were 31810. In order to
stabilize the variance the m/z with only one value were excluded
from the calculation to reach a final dataset counting 15054
individual m/z values. The intensity for each peak was normalized
to the sum of the peak intensities for each data set.
The SIMCA-P 12 (Umetrics, Umea, Sweden) software was used
to visualized and define the relation between the samples through
several multivariate methods. All statistical elaborations were done
after an Orthogonal Signal correction (OSC), in order to remove
the information that is orthogonal to Y from the independent
variables (X). We combined different multivariate techniques in
order to explain the relation between a reduced number of masses
and the ISIMatsuda value. Each model was internally validated with
7-fold cross-validation and with the permutation test.
The selection of the m/z values more related to low and high
ISI values was performed based on the highest absolute value of
the regression coefficients and on the variable importance in the
projection (VIP). The masses responsible for the metabolic
differentiation were submitted to MassTRIX using homo sapiens
as reference species and a max. error of 3 ppm. This web server
assigns to each m/z value potential annotations from KEGG
(http://www.genome.jp/kegg/), LipidMaps (http://www.lipidmaps.
org/) and HMDB [44]. In a second step MassTRIX then calls the
KEGG/API (http://www.genome.jp/kegg/soap/) to generate path-
way maps of the annotated masses.
2902 out of 15054 compounds were annotated by this
approach. Out of the 100 most important m/z VIP values, 1791
compounds were recognized from MassTRIX. 81% of the m/z
values remaining unknown show the need for further structural
investigations with orthogonal technologies (LC/MS
2 or LC/
NMR).
The statistical analyses were done with SIMCA-P 12 (Umetrics,
Umea, Sweden), SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA) and for the heatmap visualization with the statistical package
‘‘R’’ (v. 2.9.2). Statistical significance was set at p,0.05.
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